Development of idiopathic intracranial hypertension on the background of zoledronic acid therapy in Gorham-Stoat syndrome

Abstract

Idiopathic intracranial hypertension (IVH) is a condition or a heterogeneous group of vessels characterized by an increase in intracranial pressure (ICP) without signs of mass formation, hydrocephalus, infection, venous thrombosis, and hypertensive encephalopathy. The term "pseudotumoral cerebral hypertension" is used to describe the secondary origin of ICP due to various causes and is a diagnosis of exclusion. One of the risk factors for the development of IVH are hypocalcemic conditions of the development of etiology, leading to the development of ICP. Long-term use of zoledronic acid, which is a risk factor for the development of hypocalcemia, can contribute to the occurrence and fluctuating course of IVH, requires monitoring clinical monitoring of the patient's condition in order to prevent the occurrence of secondary atrophy of the optic discs, with further progressive decline and loss of vision. The choice of vaccine for a 12-year-old child with a clinically-instrumentally-histologically confirmed diagnosis of Gorham-Stout syndrome, with progressive bone resorption, receiving zoledronic acid therapy. Attracting the attention and informing a wide range of specialists in various fields about the likelihood of IVH on the background of long-term use of bone and cartilage metabolism correctors can serve as an important factor in the timely diagnosis, prevention and correction of this pathological condition in childhood.